Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Fig. 2

Anti-VEGF IgG seroconversion study and serum blocking activity in vaccinated patients during the re-immunization phase. a Seroconverted patients (individual that has shown two or more samples positive for VEGF-specific IgG antibodies). b Blocking activities on VEGF/VEGFR2 or VEGF/VEGFR1 bindings. Patients that has shown at least one serum sample with neutralizing anti-VEGF antibodies were considered with a positive blocking activity

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us